Details for Patent: 9,464,071

Which drugs does patent 9,464,071 protect, and when does it expire?

Patent 9,464,071 protects BALVERSA and is included in one NDA.

This patent has seventy-four patent family members in thirty-eight countries.

Summary for Patent: 9,464,071

Title:	Pyrazolyl quinoxaline kinase inhibitors
Abstract:	The invention relates to new quinoxaline derivative compounds, to pharmaceutical compositions comprising said compounds, to processes for the preparation of said compounds and to the use of said compounds in the treatment of diseases, e.g. cancer.
Inventor(s):	Saxty; Gordon (Cambridge, GB), Murray; Christopher William (Cambridge, GB), Berdini; Valerio (Cambridge, GB), Besong; Gilbert Ebai (Bad Duerkheim, DE), Hamlett; Christopher Charles Frederick (Cambridge, GB), Johnson; Christopher Norbert (Cambridge, GB), Woodhead; Steven John (San Diego, CA), Reader; Michael (Bishop's Stortford, GB), Rees; David Charles (Cambridge, GB), Mevellec; Laurence Anne (Louviers, FR), Angibaud; Patrick Rene (Fontaine-Bellenger, FR), Freyne; Eddy Jean Edgard (Rumst, BE), Govaerts; Tom Cornelis Hortense (Betekom, BE), Weerts; Johan Erwin Edmond (Beerse, BE), Perera; Timothy Pietro Suren (Geel, BE), Gilissen; Ronaldus Arnodus Hendrika Joseph (Kasterlee, BE), Wroblowski; Berthold (Vosselaar, BE), Lacrampe; Jean Fernand Armand (Le Mesnil-Esnard, FR), Papanikos; Alexandra (Antwerp, BE), Querolle; Olivier Alexis Georges (Evreux, FR), Pasquier; Elisabeth Therese Jeanne (Le Neubourg, FR), Pilatte; Isabelle Noelle Constance (Louviers, FR), Bonnet; Pascal Ghislain Andre (Berchem, BE), Embrechts; Werner Constant Johan (Beerse, BE), Akkari; Rhalid (Vacquieres, FR), Meerpoel; Lieven (Beerse, BE)
Assignee:	ASTEX THERAPEUTICS LTD (Cambridge, GB)
Application Number:	14/505,020
Patent Claim Types: see list of patent claims	Use;

Understanding the Scope and Claims of United States Patent 9,464,071

Introduction

United States Patent 9,464,071, titled "Pyrazolyl quinoxaline kinase inhibitors," is a patent that covers a range of chemical compounds and their applications, particularly in the field of pharmaceuticals. This article will delve into the details of the patent, including its scope, claims, and the broader patent landscape.

Overview of the Patent

The patent, assigned the number US9464071B2, was published on October 11, 2016. It relates to new quinoxaline derivative compounds, pharmaceutical compositions containing these compounds, and processes for their preparation[4].

Scope of the Patent

The scope of a patent is crucial as it defines the boundaries of what is protected. Here, the patent focuses on specific chemical compounds and their uses.

Chemical Compounds

The patent describes various quinoxaline derivatives, which are characterized by their chemical structures. These compounds include substitutions such as alkyl, alkoxy, halogen, and other functional groups. For example, the patent mentions compounds with specific groups like methyl, ethyl, and hydroxy groups[4].

Pharmaceutical Applications

The compounds are intended for use as kinase inhibitors, which are important in the treatment of various diseases, including cancer. The patent details the pharmaceutical compositions that include these compounds and how they can be administered.

Claims of the Patent

The claims section of a patent is where the inventor specifies exactly what they are seeking to protect. Here are some key aspects of the claims in US9464071B2:

Independent Claims

Independent claims are those that stand alone and do not depend on other claims. In this patent, the independent claims define the specific chemical structures of the quinoxaline derivatives and their pharmaceutical compositions. For instance, Claim 1 might describe a compound with a particular quinoxaline core and specific substituents[4].

Dependent Claims

Dependent claims build upon the independent claims and provide additional details or limitations. These claims might specify particular substituents, their positions, or other characteristics that narrow down the scope of the invention.

Metrics for Measuring Patent Scope

When analyzing the scope of a patent, metrics such as independent claim length and independent claim count can be useful. These metrics can indicate the breadth and complexity of the patent claims. For example, narrower claims at publication are associated with a higher probability of grant and a shorter examination process[3].

Patent Landscape

Understanding the broader patent landscape is essential for assessing the significance and potential impact of a patent.

Prior Art

The patent cites various prior art keywords and references, indicating the existing knowledge in the field. This includes other chemical compounds and their applications, which helps to contextualize the novelty of the invention[4].

Global Dossier and International Patent System

The USPTO's Global Dossier service allows users to view the patent family for a specific application, including related applications filed at participating IP Offices. This tool can help in understanding how this patent fits into the global patent landscape[1].

Patent Public Search

Tools like the Patent Public Search provided by the USPTO enable users to search for prior art and other published patent documentation. This is crucial for determining the novelty and non-obviousness of the invention[1].

Practical Implications

The practical implications of this patent are significant, particularly in the pharmaceutical industry.

Innovation and Competition

Patents like US9464071B2 can drive innovation by providing exclusive rights to the inventors, allowing them to invest in further research and development. However, overly broad patents can stifle competition and innovation, highlighting the importance of balanced patent scope[3].

Licensing and Litigation

The patent's scope can also impact licensing and litigation. Narrower, well-defined claims can reduce the likelihood of disputes and make licensing agreements clearer and more manageable[3].

Expert Insights

Industry experts and legal practitioners often provide valuable insights into the implications of patents.

Small Claims Patent Court

Discussions around the establishment of a small claims patent court, as studied by the Administrative Conference of the United States (ACUS), highlight the need for efficient and cost-effective mechanisms for resolving patent disputes. This could impact how patents like US9464071B2 are enforced and defended[5].

Statistics and Examples

To put the significance of this patent into perspective, consider the following statistics and examples:

Patent Maintenance Payments

Patents with narrower claims tend to have higher maintenance payments, indicating their value and the likelihood of their being maintained over time[3].

Forward Citations

The number of forward citations a patent receives can indicate its impact on subsequent innovations. Patents with significant forward citations are often considered more influential in their field[3].

Key Takeaways

• Chemical Compounds: The patent covers specific quinoxaline derivatives with various substituents.
• Pharmaceutical Applications: These compounds are intended as kinase inhibitors, crucial in treating diseases like cancer.
• Claims: Independent and dependent claims define the scope of protection, with metrics like claim length and count indicating patent breadth.
• Patent Landscape: Tools like Global Dossier and Patent Public Search help in understanding the patent's place in the global patent system.
• Practical Implications: The patent's scope affects innovation, competition, licensing, and litigation.
• Expert Insights: Discussions on small claims patent courts and patent scope metrics provide additional context.

FAQs

Q: What is the main subject of United States Patent 9,464,071? A: The main subject is new quinoxaline derivative compounds and their use as kinase inhibitors.

Q: How can one search for similar patents? A: Using tools like the USPTO's Patent Public Search or Global Dossier can help in finding related patents.

Q: What are the practical implications of this patent? A: It can drive innovation, affect competition, and influence licensing and litigation in the pharmaceutical industry.

Q: How do metrics like independent claim length and count impact patent scope? A: These metrics can indicate the breadth and complexity of the patent claims, affecting the patent's grant probability and examination process.

Q: What is the significance of forward citations for a patent? A: Forward citations indicate the patent's influence on subsequent innovations and its overall impact in the field.

Sources

1. USPTO: Search for patents - USPTO.
2. USA.gov: U.S. Patent and Trademark Office (USPTO) | USAGov.
3. SSRN: Patent Claims and Patent Scope.
4. Google Patents: US9464071B2 - Pyrazolyl quinoxaline kinase inhibitors.
5. ACUS: U.S. Patent Small Claims Court.

Drugs Protected by US Patent 9,464,071

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Janssen Biotech	BALVERSA	erdafitinib	TABLET;ORAL	212018-001	Apr 12, 2019		RX	Yes	No	9,464,071					TREATMENT OF ADULTS WITH LOCALLY ADVANCED OR METASTATIC UROTHELIAL CARCINOMA WITH SUSCEPTIBLE FGFR3 GENETIC ALTERATIONS WHOSE DISEASE HAS PROGRESSED ON OR AFTER AT LEAST ONE LINE OF PRIOR SYSTEMIC THERAPY
Janssen Biotech	BALVERSA	erdafitinib	TABLET;ORAL	212018-002	Apr 12, 2019		RX	Yes	No	9,464,071					TREATMENT OF ADULTS WITH LOCALLY ADVANCED OR METASTATIC UROTHELIAL CARCINOMA WITH SUSCEPTIBLE FGFR3 GENETIC ALTERATIONS WHOSE DISEASE HAS PROGRESSED ON OR AFTER AT LEAST ONE LINE OF PRIOR SYSTEMIC THERAPY
Janssen Biotech	BALVERSA	erdafitinib	TABLET;ORAL	212018-003	Apr 12, 2019		RX	Yes	Yes	9,464,071					TREATMENT OF ADULTS WITH LOCALLY ADVANCED OR METASTATIC UROTHELIAL CARCINOMA WITH SUSCEPTIBLE FGFR3 GENETIC ALTERATIONS WHOSE DISEASE HAS PROGRESSED ON OR AFTER AT LEAST ONE LINE OF PRIOR SYSTEMIC THERAPY

Foreign Priority and PCT Information for Patent: 9,464,071

Foriegn Application Priority Data
Foreign Country	Foreign Patent Number	Foreign Patent Date
United Kingdom	1007286.6	Apr 30, 2010

International Family Members for US Patent 9,464,071

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
African Regional IP Organization (ARIPO)	3210
Argentina	080982
Australia	2011247047
Australia	2017202512
Brazil	112012027509